JP2019110875A - Composition - Google Patents

Composition Download PDF

Info

Publication number
JP2019110875A
JP2019110875A JP2017249145A JP2017249145A JP2019110875A JP 2019110875 A JP2019110875 A JP 2019110875A JP 2017249145 A JP2017249145 A JP 2017249145A JP 2017249145 A JP2017249145 A JP 2017249145A JP 2019110875 A JP2019110875 A JP 2019110875A
Authority
JP
Japan
Prior art keywords
calcium
composition
mass
tea
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017249145A
Other languages
Japanese (ja)
Other versions
JP6399419B1 (en
Inventor
仁人 鍔田
Masahito Tsubata
仁人 鍔田
高垣 欣也
Kinya Takagaki
欣也 高垣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Shinyaku Co Ltd
Original Assignee
Toyo Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Shinyaku Co Ltd filed Critical Toyo Shinyaku Co Ltd
Priority to JP2017249145A priority Critical patent/JP6399419B1/en
Application granted granted Critical
Publication of JP6399419B1 publication Critical patent/JP6399419B1/en
Publication of JP2019110875A publication Critical patent/JP2019110875A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Non-Alcoholic Beverages (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Tea And Coffee (AREA)

Abstract

To provide a composition that can effectively use saponarin, one of flavonoids, or a composition having an excellent calcium absorption promoting action as a new use for saponarin.SOLUTION: A composition contains 0.00001-20 mass%, preferably 0.0001-15 mass%, more preferably 0.001-10 mass% of saponarin, and 0.001-50 mass%, preferably 0.01-45 mass%, more preferably 0.1-40 mass% of calcium, and further contains unfermented tea and lactic acid bacteria.SELECTED DRAWING: Figure 1

Description

本発明は、サポナリンとカルシウムを含有する組成物に関する。 The present invention relates to a composition containing saponalin and calcium.

サポナリンは、フラボノイドの一種であり、従来から植物の花に含有されていることが知られている。このサポナリンを含む植物としてムクゲが知られており、その花を乾燥させたものは、木槿花として漢方に用いられている。しかし、サポナリン自体は、毒性がなく安全であることが知られているにも関わらず、殆ど利用されていないのが現状である。そこで、サポナリンを有効に利用することが出来る新たな組成物の開発が必要とされている。 Saponarin is a kind of flavonoid and is conventionally known to be contained in the flowers of plants. As a plant containing this saponalin, mkuge is known, and the one obtained by drying the flower is used in traditional Chinese medicine as a xylophone. However, despite the fact that saponarin itself is known to be non-toxic and safe, it is hardly used at present. Thus, there is a need to develop new compositions that can effectively utilize saponalins.

生体において重要な役割を果たす2価カチオンであるカルシウムは、骨や歯を形成する主要なミネラルとして知られている。例えば、腸で吸収されて血液中に入ったカルシウムは、骨代謝に使用され、健全な状態では、骨吸収と骨形成によるバランスがとられた骨代謝がみられる。しかし、カルシウム摂取量の低下などにより、骨代謝の異常が生じると骨量の減少を招き、骨粗鬆症や骨折などの骨関連疾患が生じる。 Calcium, which is a divalent cation that plays an important role in the living body, is known as a major mineral that forms bones and teeth. For example, calcium that is absorbed in the intestine and enters the blood is used for bone metabolism, and in a healthy state, there is bone metabolism that is balanced by bone resorption and bone formation. However, due to a decrease in calcium intake and the like, an abnormality in bone metabolism causes a decrease in bone mass, resulting in bone-related diseases such as osteoporosis and fractures.

また、体内のカルシウムの一部は骨や歯以外の細胞や血液中に一定濃度で存在し、神経や筋肉の興奮、血液凝固などの観点で重要な役割を果している。そこで、血液中のカルシウムが不足すると、神経、筋肉、血液などの異常に基づく疾患や骨吸収が進むことによる骨関連疾患などがみられるようになる。 In addition, part of calcium in the body exists in cells and blood other than bones and teeth at a constant concentration, and plays an important role in terms of nerve and muscle excitation, blood coagulation, and the like. Therefore, when calcium in the blood is insufficient, diseases based on abnormalities of nerves, muscles, blood and the like, bone-related diseases due to progress of bone resorption, and the like will be seen.

このようにカルシウムは、生物の基本的な必須元素であり、多様な生理作用を示すものとして重要な役割を有している。このカルシウムとサポナリンとを組み合わせることによって、有用性が得られるのであれば、サポナリンの有効利用に多大な貢献ができるものである。 Thus, calcium is a basic essential element of an organism, and plays an important role as a variety of physiological actions. If the combination of calcium and saponalin can be useful, it can greatly contribute to the effective use of saponalin.

そこで、本発明は、サポナリンを有効に利用することが出来る新たな組成物を提供することを発明が解決しようとする課題とする。また、サポナリンの新たな有用性として、カルシウム吸収促進作用を有する組成物を提供することも発明が解決しようとする課題とする。 Then, this invention makes it a subject which an invention tends to solve to provide the new composition which can utilize saponarin effectively. Another object of the invention is to provide a composition having a calcium absorption promoting action as a new utility of saponarin.

本出願人は、上記課題を鑑みて鋭意検討を行った結果、毒性がなく安全であることが知られているサポナリンとカルシウムとを組み合わせることで、格別優れたカルシウム吸収促進作用を示すことを見出し、本発明に至った。 As a result of intensive investigations in light of the above problems, the present applicant has found that combining saponalin and calcium, which is known to be nontoxic and safe, exhibits an excellent calcium absorption promoting action. The present invention has been achieved.

本発明の概要は、以下の通りである。
<1>サポナリン及びカルシウムを含有する組成物。
<2>さらに、不発酵茶を含有する<1>に記載の組成物。
<3>さらに、乳酸菌を含有する<2>に記載の組成物。

<4>カルシウム吸収促進用である<1>〜<3>のいずれかに記載の組成物。
<5>飲食品である<1>〜<4>のいずれかに記載の組成物。
The summary of the present invention is as follows.
<1> A composition containing saponalin and calcium.
<2> The composition according to <1>, further comprising unfermented tea.
<3> The composition according to <2>, further comprising a lactic acid bacterium.

The composition in any one of <1>-<3> which is for <4> calcium absorption promotion.
The composition in any one of <1>-<4> which is <5> food-drinks.

本発明の組成物は、サポナリンの新たな有用性を提供できる。また、本発明のサポナリンとカルシウムを含有する組成物は、優れたカルシウム吸収促進作用を提供できる。 The compositions of the present invention can provide new utilities for saponalins. In addition, the composition containing saponalin and calcium of the present invention can provide an excellent calcium absorption promoting action.

実施例1〜4の比較例1に対するカルシウム吸収量の変化値を表す図である。It is a figure showing the change value of the amount of calcium absorption to comparative example 1 of Examples 1-4.

以下、本発明の組成物について説明する。なお、本発明は、下記の実施の形態に限定されるものではない。 Hereinafter, the composition of the present invention will be described. The present invention is not limited to the following embodiment.

(A)カルシウム
カルシウムは、元素記号Caで表される金属元素であり、カルシウム単体だけでなく、カルシウムと他の元素や陰イオンが結合した化合物のことも指す。カルシウムは通常知られているとおりのものであれば特に限定されず、例えば、市販の炭酸カルシウム、ケイ酸カルシウム、リン酸カルシウム、塩化カルシウムなどの無機塩又は有機塩が用いられる。これらの中でも、炭酸カルシウムが安定性や風味の観点から好ましい。炭酸カルシウムを用いる場合、その由来は特に限定されないが、卵殻カルシウム、ホタテ貝殻カルシウム、サンゴカルシウムなどが好ましく、安全性が高いといった観点から、サンゴカルシウムが特に好ましい。これらのカルシウムは1種を単独で又は2種以上を組み合わせて用いることができる。
(A) Calcium Calcium is a metal element represented by the symbol of element Ca, and refers not only to calcium alone but also to a compound in which calcium and another element or anion are bonded. Calcium is not particularly limited as long as it is generally known, and commercially available inorganic salts or organic salts such as calcium carbonate, calcium silicate, calcium phosphate and calcium chloride are used. Among these, calcium carbonate is preferable from the viewpoint of stability and flavor. When calcium carbonate is used, its origin is not particularly limited, but eggshell calcium, scallop calcium, coral calcium and the like are preferable, and coral calcium is particularly preferable from the viewpoint of high safety. These calcium can be used individually by 1 type or in combination of 2 or more types.

本発明の組成物に配合されるカルシウムの含有量としては、特に制限はなく、目的や形状、使用対象等の様々な条件に応じて、広範囲でその含有量を適宜設定できる。例えば、0.001〜50質量%、好ましくは0.01〜45質量%、より好ましくは0.1〜40質量%の範囲で選択される。本発明においては、市販品を使用してもよく、また当該分野で公知の方法で製造したものを使用することもできる。 There is no restriction | limiting in particular as content of calcium mix | blended with the composition of this invention, According to various conditions, such as an objective, a shape, and use object, the content can be suitably set in a wide range. For example, it is selected in the range of 0.001 to 50% by mass, preferably 0.01 to 45% by mass, and more preferably 0.1 to 40% by mass. In the present invention, commercially available products may be used, and those produced by methods known in the art may also be used.

(B)サポナリン
サポナリン(CAS番号:20310−89−8)は、イソビテキシン(サポナレチン)の7−O−グルコシドを指し、ムクゲ、ヒスイカズラ、ザボンソウ、トケイソウ、サポナリア(シャボンソウ、ソープワート)、オオムギ、サトウキビ、フヨウなどの植物に含まれることが知られている。本発明に使用されるサポナリンは、特に限定されないが、当業者により通常知られている方法によって製造したものでもよいし、市販品であってもよい。サポナリンは、サポナリンを含有する植物、例えば、花、葉、茎又はこれらに破砕・粉砕等の処理を行った加工物を直接用いても良いし、分離・抽出等又は人工的に合成する等の方法で得るものを用いてもよい。
(B) Saponarin Saponarin (CAS number: 20310-89-8) refers to a 7-O-glucoside of isobitexin (saponaretin), which is a mauve, red sea bream, red sea bream, bonito flower, sun flower, saponaria (soap grass), barley It is known to be included in plants such as sugar cane and pheasant. The saponalin used in the present invention is not particularly limited, and may be produced by a method generally known by those skilled in the art or may be a commercially available product. For saponalins, plants containing saponarins, such as flowers, leaves, stems, or processed products obtained by subjecting them to crushing or crushing may be used directly, or they may be separated / extracted or artificially synthesized, etc. You may use what is obtained by a method.

原料からサポナリンを得るための破砕・粉砕処理方法は、特に限定されず、湿式・乾式どちらでも良く、粉砕条件、処理装置も特に限定されず、市販の装置等を適宜使用することができる。使用する装置としては、例えば、高圧ホモジェナイザー、超音波粉砕機、気流式粉砕機、高速回転衝撃粉砕機、ボールミル又はビーズミル等が挙げられる。これらの処理は、加工物の粒径等の物性が好ましい範囲内になるよう、必要に応じて複数回繰り返しても良く、複数の処理を組み合わせても良い。また、原料からのサポナリンの抽出・分離方法及び合成方法は特に限定されず、目的に応じて適宜選択することができる。抽出方法としては、例えば、エタノール、水、含水エタノール等の当業者が通常用いる抽出溶媒を加え、必要に応じて加温して抽出する方法等を挙げることができる。 The crushing / pulverizing method for obtaining saponalin from the raw material is not particularly limited, and either wet or dry may be used, and the pulverizing conditions and the treatment apparatus are not particularly limited, and commercially available apparatuses and the like can be appropriately used. As an apparatus to be used, for example, a high pressure homogenizer, an ultrasonic crusher, an air flow crusher, a high speed rotary impact crusher, a ball mill, a bead mill or the like can be mentioned. These treatments may be repeated a plurality of times as necessary so that physical properties such as the particle diameter of the processed product fall within a preferable range, and a plurality of treatments may be combined. Further, the method for extracting and separating saponalin from the raw material and the synthesis method are not particularly limited, and can be appropriately selected according to the purpose. Examples of the extraction method include a method of adding an extraction solvent usually used by those skilled in the art such as ethanol, water, water-containing ethanol and the like, and heating and extracting as necessary.

本発明の組成物に配合されるサポナリンの含有量としては、特に制限はなく、目的や形状、使用対象等の様々な条件に応じて、広範囲でその含有量を適宜設定できる。例えば、0.00001〜20質量%、好ましくは0.0001〜15質量%、より好ましくは0.001〜10質量%の範囲で選択される。 There is no restriction | limiting in particular as content of the saponarin mix | blended with the composition of this invention, According to various conditions, such as an objective, a shape, and use object, the content can be set suitably over a wide range. For example, it is selected in the range of 0.00001 to 20% by mass, preferably 0.0001 to 15% by mass, and more preferably 0.001 to 10% by mass.

(C)不発酵茶
本発明で使用される不発酵茶は、ツバキ科、チャノキ属チャノキ(Camellia sinensis)の植物の葉、すなわち茶葉を由来とする緑茶であり、緑茶としては、例えば、抹茶や碾茶、煎茶、かぶせ茶、番茶、茎茶、粉茶等がある。
(C) Unfermented Tea The infermented tea used in the present invention is a leaf of a plant of camellia, tea tree genus Camellia (Camellia sinensis), that is, green tea derived from tea leaves, and as green tea, for example, matcha or green tea There are apricot tea, sencha, capricha, bancha, stem tea, powdered tea and so on.

本発明で用いる不発酵茶は、茶葉の乾燥物、茶葉の粉砕物及びその乾燥粉末(粉砕末)、茶葉の搾汁及びその乾燥粉末(搾汁末)、茶葉のエキス及びその乾燥粉末(エキス末)などが挙げられる。茶葉の粉砕末を得る場合、その粉砕処理方法は、特に限定されず、湿式・乾式どちらでも良く、粉砕条件、処理装置も特に限定されず、市販の装置等を適宜使用することができる。使用する装置としては、例えば、高圧ホモジェナイザー、超音波粉砕機、気流式粉砕機、高速回転衝撃粉砕機、ボールミル又はビーズミル等が挙げられる。これらの処理は、加工物の粒径等の物性が好ましい範囲内になるよう、必要に応じて複数回繰り返しても良く、複数の処理を組み合わせても良い。茶葉のエキスを得る場合、その抽出溶媒は特に限定はされないが、例えば、水、アルコール(例えば、メタノール、エタノール、n−プロパノール、n−ブタノールなど)、アセトンなどの溶媒が挙げられ、好ましくは、水および/またはエタノールなどを使用することができる。また、その乾燥粉末を得る場合は、例えば減圧乾燥や噴霧乾燥等、当業者が通常用いる方法によりエキスの溶媒を除去することで得ることができる。 The non-fermented tea used in the present invention is a dried tea leaf, a crushed tea leaf and its dried powder (ground powder), a tea leaf juice and its dried powder (juice powder), a tea leaf extract and its dried powder (extract End) and so on. In the case of obtaining a ground powder of tea leaves, the method of grinding treatment is not particularly limited, and either wet or dry treatment may be used, and the grinding conditions and the treatment apparatus are not particularly limited, and commercially available devices and the like can be used appropriately. As an apparatus to be used, for example, a high pressure homogenizer, an ultrasonic crusher, an air flow crusher, a high speed rotary impact crusher, a ball mill, a bead mill or the like can be mentioned. These treatments may be repeated a plurality of times as necessary so that physical properties such as the particle diameter of the processed product fall within a preferable range, and a plurality of treatments may be combined. When the tea leaf extract is obtained, the extraction solvent is not particularly limited, and examples thereof include solvents such as water, alcohol (for example, methanol, ethanol, n-propanol, n-butanol and the like), acetone and the like, and preferably Water and / or ethanol can be used. Moreover, when obtaining the dry powder, it can obtain by removing the solvent of an extract, for example by methods normally used by persons skilled in the art, such as reduced-pressure drying and spray-drying.

不発酵茶の製造方法は特に限定されず、当業者が通常用いる方法により得ることができる。本発明においては、加工性や安定性の観点から、不発酵茶の粉末が好ましく使用され、特に、エキス末、粉砕末を用いることが好ましく、茶葉に含まれる成分をそのまま摂取することが出来る粉砕末がより好ましく、とりわけ抹茶が好ましい。 The method for producing unfermented tea is not particularly limited, and can be obtained by methods commonly used by those skilled in the art. In the present invention, in view of processability and stability, powder of unfermented tea is preferably used, and it is particularly preferable to use extract powder and pulverized powder, and pulverization in which ingredients contained in tea leaves can be consumed as it is Ginseng is more preferable, and in particular, Matcha is preferable.

本発明の組成物に配合される不発酵茶の含有量としては、特に制限はなく、目的や形状、使用対象等の様々な条件に応じて、広範囲でその含有量を適宜設定できる。例えば、0.01〜40質量%、好ましくは0.05〜30質量%、より好ましくは0.01〜25質量%の範囲で選択される。本発明においては、市販品を使用してもよく、また当該分野で公知の方法で製造したものを使用することもできる。 There is no restriction | limiting in particular as content of the non-fermented tea mix | blended with the composition of this invention, According to various conditions, such as an objective, a shape, and use object, the content can be set suitably over a wide range. For example, it is selected in the range of 0.01 to 40% by mass, preferably 0.05 to 30% by mass, and more preferably 0.01 to 25% by mass. In the present invention, commercially available products may be used, and those produced by methods known in the art may also be used.

(D)乳酸菌
乳酸菌は、代謝によって乳酸を生成する細菌類のことを指す。乳酸菌は通常知られているとおりのものであれば特に限定されず、例えば、Streptococcus faecalis(Enterococcus faecalisと称されることがある)、Lactobacillus acidophilus、Lactobacillus casei、Streptococcus thermophilus及びBacillus coagullansなどが用いられるが、人由来で安全性が高いといった観点から、Streptococcus faecalisが特に好ましい。これらの乳酸菌は1種を単独で又は2種以上を組み合わせて用いることができる。これらの乳酸菌の入手方法としては、特に制限はなく、例えばヨーグルトや野菜などの食品から単離された乳酸菌や市販品を用いてもよい。
(D) Lactic acid bacteria Lactic acid bacteria refer to bacteria that produce lactic acid by metabolism. Lactic acid bacteria are not particularly limited as long as they are generally known, and for example, Streptococcus faecalis (sometimes referred to as Enterococcus faecalis), Lactobacillus acidophilus, Lactobacillus casei, Streptococcus thermophilus, Bacillus coagullans, etc. may be used. Streptococcus faecalis is particularly preferable from the viewpoints of human origin and high safety. These lactic acid bacteria can be used singly or in combination of two or more. There is no restriction | limiting in particular as a method of obtaining these lactic acid bacteria, For example, you may use lactic acid bacteria isolated from foodstuffs, such as yogurt and vegetables, and a commercial item.

本発明の組成物に配合される乳酸菌の含有量としては、特に制限はなく、目的や形状、使用対象等の様々な条件に応じて、広範囲でその含有量を適宜設定できる。例えば、0.0001〜20質量%、好ましくは0.001〜15質量%、より好ましくは0.01〜10質量%の範囲で選択される。 There is no restriction | limiting in particular as content of the lactic acid bacteria mix | blended with the composition of this invention, According to various conditions, such as an objective, a shape, and use object, the content can be set suitably in a wide range. For example, it is selected in the range of 0.0001 to 20% by mass, preferably 0.001 to 15% by mass, and more preferably 0.01 to 10% by mass.

本発明の組成物における、(A)カルシウムと(B)サポナリンの配合比(質量比)は特に限定されず、目的や使用対象等の条件に応じて適宜設定できるが、本発明の効果を高める観点から、例えば(A):(B)=1:0.000001〜100、好ましくは1:0.00001〜50、より好ましくは1:0.0001〜30の範囲で選択される。 The compounding ratio (mass ratio) of (A) calcium and (B) saponalin in the composition of the present invention is not particularly limited, and can be appropriately set according to the conditions such as the purpose and the use object, but enhances the effect of the present invention From the viewpoint, for example, (A): (B) = 1: 0.000001 to 100, preferably 1: 0.00001 to 50, more preferably 1: 0.0001 to 30.

本発明の組成物における、(A)カルシウム及び(B)サポナリンと(C)不発酵茶の配合比(質量比)は特に限定されず、目的や使用対象等の条件に応じて適宜設定できるが、本発明の効果を高める観点から、例えば(A)+(B):(C)=1:0.00001〜100、好ましくは1:0.0001〜50、より好ましくは1:0.001〜30の範囲で選択される。 The compounding ratio (mass ratio) of (A) calcium and (B) saponalin and (C) infermented tea in the composition of the present invention is not particularly limited, and can be appropriately set according to the conditions such as the purpose and object of use. From the viewpoint of enhancing the effects of the present invention, for example, (A) + (B) :( C) = 1: 0.00001 to 100, preferably 1: 0.0001 to 50, more preferably 1: 0.001 to It is selected in the range of 30.

本発明の組成物における、(A)カルシウム及び(B)サポナリンと(D)乳酸菌の配合比(質量比)は特に限定されず、目的や使用対象等の条件に応じて適宜設定できるが、本発明の効果を高める観点から、例えば(A)+(B):(D)=1:0.001〜100、好ましくは1:0.01〜50、より好ましくは1:0.1〜30の範囲で選択される。 The blending ratio (mass ratio) of (A) calcium and (B) saponalin to (D) lactic acid bacteria in the composition of the present invention is not particularly limited, and can be appropriately set according to the conditions such as the purpose and the use target. From the viewpoint of enhancing the effects of the invention, for example, (A) + (B) :( D) = 1: 0.001 to 100, preferably 1: 0.01 to 50, more preferably 1: 0.1 to 30 It is selected by the range.

本発明の組成物における、(B)サポナリンと(C)不発酵茶の配合比(質量比)は特に限定されず、目的や使用対象等の条件に応じて適宜設定できるが、例えば本発明の効果を高める観点から、(B):(C)=1:0.001〜150、好ましくは1:0.01〜100、より好ましくは1:0.1〜50の範囲で選択される。 Although the compounding ratio (mass ratio) of (B) saponalin and (C) infermented tea in the composition of this invention is not specifically limited, According to conditions, such as an objective and a use object, it can set suitably, for example From the viewpoint of enhancing the effect, it is selected in the range of (B) :( C) = 1: 0.001 to 150, preferably 1: 0.01 to 100, more preferably 1: 0.1 to 50.

本発明の組成物における、(B)サポナリンと(D)乳酸菌の配合比(質量比)は特に限定されず、目的や使用対象等の条件に応じて適宜設定できるが、例えば本発明の効果を高める観点から、(B):(D)=1:0.001〜200、好ましくは1:0.01〜150、より好ましくは1:0.1〜125の範囲で選択される。 The compounding ratio (mass ratio) of (B) saponalin and (D) lactic acid bacteria in the composition of the present invention is not particularly limited, and can be appropriately set according to the conditions such as the purpose and the use object. From the viewpoint of enhancing (B): (D) = 1: 0.001 to 200, preferably 1: 1: 0.01 to 150, more preferably 1: 1: 0.1 to 125.

本発明の組成物における、(C)不発酵茶と(D)乳酸菌の配合比(質量比)は特に限定されず、目的や使用対象等の条件に応じて適宜設定できるが、例えば本発明の効果を高める観点から、(C):(D)=1:0.0001〜100、好ましくは1:0.001〜50、より好ましくは1:0.01〜30の範囲で選択される。 The compounding ratio (mass ratio) of (C) infermented tea to (D) lactic acid bacteria in the composition of the present invention is not particularly limited, and can be appropriately set according to the conditions such as the purpose and the use object. From the viewpoint of enhancing the effect, it is selected in the range of (C) :( D) = 1: 0.0001 to 100, preferably 1: 0.001 to 50, and more preferably 1: 0.01 to 30.

本発明の組成物には、カルシウム、サポナリン、不発酵茶及び乳酸菌以外に、その他の成分を含有しても良い。前記のその他の成分としては、例えば、タンパク質、植物又は植物加工品、藻類、酵母等の微生物等を配合することができる。更に必要に応じて通常食品分野で用いられる、デキストリン、でんぷん等の糖類、甘味料、酸味料、着色料、増粘剤、光沢剤、賦形剤、ビタミン類、栄養補助剤、結合剤、滑沢剤、安定剤、希釈剤、増量剤、乳化剤、食品添加物、調味料等を挙げることができる。これらその他の成分の含有量は、本発明の組成物の形態等に応じて適宜選択することができる。 The composition of the present invention may contain other components in addition to calcium, saponalin, unfermented tea and lactic acid bacteria. As said other components, microorganisms, such as protein, processed products of plants or plants, algae, yeast, etc. can be mix | blended, for example. Furthermore, dextrin, saccharides such as starch, sweeteners, acidulants, colorants, thickeners, brighteners, excipients, vitamins, nutritional supplements, binders, lubricants, which are usually used in the food field, if necessary. There may be mentioned fillers, stabilizers, diluents, fillers, emulsifiers, food additives, seasonings and the like. The content of these other components can be appropriately selected according to the form of the composition of the present invention and the like.

本発明の組成物の形態は特に限定されず、任意の形態とすることができる。具体的な形態としては、例えば、粉や顆粒、細粒等の粉末状、タブレット(チュアブル)状、球状、カプセル状、カプレット状、液状等の形状が挙げられる。尚、カプセル状の組成物は、ソフトカプセル及びハードカプセルが含まれる。本発明の組成物は、粉や顆粒、細粒等の粉末状が好ましく、特に、水などと混合し、溶解したり懸濁させたりして使用する粉末飲料とすることにより、組成物としての安定性にも優れるとともに、カプセルや錠剤等と異なり1度に多くの組成物を摂取することができるので好ましい。 The form of the composition of the present invention is not particularly limited and can be any form. As a specific form, for example, a powder, such as powder, granules, powder such as fine granules, a tablet (chewable), a sphere, a capsule, a caplet, a liquid or the like can be mentioned. The capsule-like composition includes soft capsules and hard capsules. The composition of the present invention is preferably in the form of powder, such as powder, granules, fine particles, etc., and in particular, it is mixed with water or the like and dissolved or suspended to form a powdered beverage to be used. It is preferable because it is excellent in stability and can take many compositions at a time unlike capsules and tablets.

本発明の組成物は、従来公知の方法により製造することができる。本発明の組成物を製造する際、使用する原料の形態は特に限定されず、組成物の形態に合わせて適宜選択し、使用することができる。例えば、粉や顆粒、細粒等の粉末状の組成物を得る場合、カルシウム、サポナリン、不発酵茶及び乳酸菌は、これらをそのまま使用しても良いし、賦形剤、増量剤等との混合物を使用しても良い。また、カプセル状の組成物を得る場合は、水や食用油等の溶媒にあらかじめ溶解又は分散させたものを使用しても良い。 The composition of the present invention can be produced by a conventionally known method. When manufacturing the composition of this invention, the form of the raw material to be used is not specifically limited, According to the form of a composition, it can select suitably and can be used. For example, in the case of obtaining a powdery composition such as powder, granules or fine granules, calcium, saponalin, infermented tea and lactic acid bacteria may be used as they are, or they may be mixed with excipients, extenders, etc. You may use Moreover, when obtaining a capsule-like composition, you may use what was melt | dissolved or disperse | distributed beforehand in solvent, such as water and an edible oil.

本発明の組成物を有効利用する方法として、本発明の組成物を使用した製品の本体、包装、説明書、宣伝物のいずれかにカルシウムを摂取することによって得られる作用を表示して用いることができる。例えば、製品としては、医薬品(医薬部外品を含む)や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品等が挙げられる。いわゆる健康食品においては、「骨の健康維持に」、「骨の健康が気になる方に」、「歯の健康が気になる方に」、「カルシウム補給に」、等を表示したものを例示することができる。 As a method of effectively using the composition of the present invention, displaying and using the effect obtained by taking calcium into the body of the product using the composition of the present invention, a package, an instruction, or a promotional item Can. For example, as products, so-called health food such as pharmaceuticals (including quasi-drugs), food for specified health use, food for nutritional function, food for functional indication, etc. Etc. In so-called health food products, those displaying "for maintaining bone health", "for those concerned about bone health", "for those concerned about dental health", "for calcium supplementation", etc. It can be illustrated.

本発明の組成物は、カルシウム吸収を促進することができるため、カルシウム吸収促進用組成物、カルシウム吸収サポート用組成物、カルシウム補給用組成物、カルシウム摂取用組成物などとして使用できるほか、カルシウム吸収促進用飲食品組成物、カルシウム吸収サポート用飲食品組成物、カルシウム補給用飲食品組成物、カルシウム摂取用飲食品組成物、カルシウム吸収促進用剤、カルシウム吸収サポート用剤、カルシウム補給用剤、カルシウム摂取用剤などとしても使用することが出来る。 Since the composition of the present invention can promote calcium absorption, it can be used as a calcium absorption promoting composition, a composition for calcium absorption support, a composition for calcium supplement, a composition for calcium intake, etc. Food and drink composition for promoting, food and drink composition for calcium absorption support, food and drink composition for calcium supplement, food and drink composition for calcium intake, agent for calcium absorption promotion, agent for calcium absorption support, agent for calcium supplement, calcium It can also be used as an intake agent.

以下、本発明を実施例により具体的に説明する。なお、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be specifically described by way of examples. The present invention is not limited to these examples.

[試験例 カルシウム吸収試験]
(試験方法)
ヒト結腸腺癌由来細胞(Caco−2)を24wellプレート(基底膜側ウェル)に装着したインサートウェル(粘膜側ウェル)に4.0×10cells/wellの細胞密度で播種して培養した。培地はDMEM培地に10% FBSと1% Non−essential Amino Acid Solutionを添加したものを用いた。5%COインキュベーター内で14〜15日間培養し、Caco−2単層膜を作製した。
[Test example calcium absorption test]
(Test method)
Human colon adenocarcinoma-derived cells (Caco-2) were seeded and cultured at a cell density of 4.0 × 10 4 cells / well in insert wells (mucosal wells) attached to a 24-well plate (basal membrane side wells). The medium used was DMEM medium supplemented with 10% FBS and 1% non-essential Amino Acid Solution. The cells were cultured in a 5% CO 2 incubator for 14 to 15 days to prepare Caco-2 monolayer membranes.

インサートウェルを、カルシウムを含まないBuffer(Hanks balanced salt solution、10mM HEPES)にて洗浄後、1000μLのBufferが入った24wellプレートに移し、インサートウェルに350μLのBufferを入れて30分間インキュベーター内で馴化させた。 After washing the insert well with calcium-free buffer (Hanks balanced salt solution, 10 mM HEPES), transfer it to a 24-well plate containing 1000 μL of Buffer, add 350 μL of buffer to the insert well and acclimate in an incubator for 30 minutes. The

馴化後、インサートウェル内のBufferを175μL除去し、以下に記載する方法に従って調整した被験物質の各溶液を、後述の表1に示す最終濃度になるようにインサートウェルに合計175μL添加し、COインキュベーター内で3時間培養した。
・カルシウム又は乳酸菌:0.5%DMSO含有Bufferで10mg/mLの溶液に調製し、0.5%DMSO含有Bufferで適宜希釈して用いた。
・サポナリン:100%DMSOで200mg/mLに溶解し、その後Bufferで1mg/mLの溶液に調製し、0.5%DMSO含有Bufferで適宜希釈して用いた。
・不発酵茶:0.5%DMSO含有Bufferで10mg/mLに調製後、15,000rpmで5分間遠心分離して得られた上清(溶液)を回収し、0.5%DMSO含有Bufferで適宜希釈して用いた。
なお、不発酵茶については溶液回収前の濃度(10mg/mL)を基に、表1に示す最終濃度になるようにインサートウェルに添加した。コントロールはカルシウムを含有しない0.5%DMSO含有Buffer175μLを添加した。
After habituation, a Buffer in the insert wells was 175μL removed, each solution of the test substance was prepared according to the method described below, a total of 175μL was added to the insert wells to a final concentration shown in Table 1 below, CO 2 The cells were cultured for 3 hours in an incubator.
-Calcium or lactic acid bacteria: prepared in a solution of 10 mg / mL with Buffer containing 0.5% DMSO, and used appropriately diluted with Buffer containing 0.5% DMSO.
Saponarin: dissolved in 200 mg / mL in 100% DMSO, then prepared into a 1 mg / mL solution in Buffer, and appropriately diluted in Buffer containing 0.5% DMSO and used.
· Infermented tea: After preparation to 10 mg / mL with Buffer containing 0.5% DMSO, the supernatant (solution) obtained by centrifuging at 15,000 rpm for 5 minutes is collected, and Buffered with 0.5% DMSO. It diluted suitably and used.
In addition, about unfermented tea, it added to the insert well so that it might become the final concentration shown in Table 1 based on the density | concentration (10 mg / mL) before solution collection | recovery. As a control, 175 μL of buffer containing 0.5% DMSO containing no calcium was added.

培養後、24wellプレートのBufferを回収し、遠心エバポレーター(東京理化器械株式会社製)で一定量に濃縮した後、メタロアッセイカルシウム(Ca)測定 LS(CPZIII)キット(メタロジェニクス株式会社製)を用いて、Caco−2単層膜を透過したカルシウム量を測定した。測定した各群の値から、コントロールの値を差し引いた値を算出し、比較例の値を100とした時の相対値を算出した。なお、腸管を透過したカルシウムは体内に吸収されるため、Caco−2単層膜を透過したカルシウム量を以降は吸収量と記載する。 After incubation, collect 24 well plate of Buffer, concentrate to a fixed volume with a centrifugal evaporator (manufactured by Tokyo Rika Kikai Co., Ltd.), and measure metalloassay calcium (Ca). The amount of calcium that permeated the Caco-2 monolayer membrane was measured using this. The value which deducted the value of control was computed from the value of each measured group, and the relative value when the value of a comparative example was set to 100 was computed. In addition, since calcium which permeate | transmitted the intestinal tract is absorbed in the body, the amount of calcium which permeate | transmitted Caco-2 single layer film is hereafter described as absorption.

また、比較例のカルシウム吸収量からの変化値を下記の式にて算出し、カルシウム吸収促進作用を評価した。
カルシウム吸収量の変化値=(各被験物質を添加したサンプルのカルシウム吸収量)−100
Moreover, the change value from the calcium absorption amount of a comparative example was computed by the following formula, and the calcium absorption promotion effect was evaluated.
Change value of calcium absorption amount = (calcium absorption amount of sample to which each test substance was added)-100

(測定結果)
各試験区の被験物質を表1に示す。各試験区の数値は各成分の最終濃度を示し、単位はいずれもμg/mLである。被験物質として、カルシウムは市販されている粉末状のサンゴカルシウム(カルシウム規定値 10%)を、サポナリンは市販されている試薬を、不発酵茶は市販されている抹茶を、乳酸菌は市販されている粉末状のStreptococcus faecalisの乾燥菌体をそれぞれ用いた。
(Measurement result)
The test substances in each test area are shown in Table 1. The numerical value in each test section indicates the final concentration of each component, and all units are μg / mL. As a test substance, calcium is commercially available powdered coral calcium (calcium standard value 10%), saponalin is commercially available reagent, unfermented tea is commercially available matcha green tea, and lactic acid bacteria are commercially available Powdered dried Streptococcus faecalis dry cells were used respectively.

比較例のカルシウム吸収量からの変化値を図1のグラフに示す。図1に示すように、サンゴカルシウムとサポナリンとを含有する実施例1は、サンゴカルシウムのみを含有する比較例1よりもカルシウムの吸収量が高くなった。サンゴカルシウムとサポナリンに加えて抹茶を含有する実施例2は、抹茶を含有しない実施例1と比較してもさらにカルシウムの吸収量は高くなった。一方、サンゴカルシウムとサポナリンに加えて乳酸菌を含有する実施例3は、実施例2のようにカルシウム吸収量は高くならず、実施例2の変化値が27.0であったのに対し、実施例2の変化値は14.1と、実施例1の変化値17.7よりも低くなった。しかしながら驚くべきことに、サンゴカルシウムとサポナリンに加えて抹茶と乳酸菌とを含有する実施例4は、カルシウム吸収量の変化値が実施例2よりも約2倍程度高くなっており、比較例1の吸収量と比較して50%以上も高くなった。その理由は不明だが、サポナリン、抹茶及び乳酸菌の組み合わせにより、相乗的な効果が奏された可能性が推測できる。 The change value from the calcium absorption of the comparative example is shown in the graph of FIG. As shown in FIG. 1, Example 1 containing coral calcium and saponalin had higher calcium absorption than Comparative Example 1 containing only coral calcium. Example 2 which contains matcha calcium in addition to coral calcium and saponarin has a higher calcium absorption even when compared to Example 1 which does not contain matcha. On the other hand, Example 3 which contains lactic acid bacteria in addition to coral calcium and saponal does not have a high calcium absorption amount as in Example 2, whereas the change value of Example 2 is 27.0, but is performed The change value of Example 2 was 14.1 which is lower than the change value 17.7 of Example 1. However, it is surprising that Example 4 containing coral tea and saponalin in addition to matcha and lactic acid bacteria has a change in calcium absorption that is about twice as high as that in Example 2 and Comparative Example 1 It is more than 50% higher than the amount absorbed. Although the reason is unknown, it can be speculated that the combination of saponalin, matcha and lactic acid bacteria may have a synergistic effect.

以上の結果より、カルシウムのみを含む組成物(組成物I)よりもカルシウムとサポナリンとを含有する組成物(組成物II)はカルシウム吸収促進作用に優れており、組成物IIに加えて抹茶を含む組成物(組成物III)はさらにカルシウム吸収促進作用に優れることがわかった。一方、組成物IIに加えて乳酸菌を含む組成物(組成物IV)は組成物IIIのようにサポナリンによるカルシウム吸収促進作用が高まることはなく、むしろ低まることがわかった。しかしながら予想外なことに、組成物IIに加えて、抹茶と乳酸菌を含む組成物(組成物V)は、カルシウム吸収促進作用が極めて優れることがわかった。 From the above results, the composition containing calcium and saponalin (composition II) is superior to the composition containing calcium alone (composition I) in the calcium absorption promoting action, and in addition to the composition II, matcha is added to the composition II. It was found that the composition containing (Composition III) is further excellent in the calcium absorption promoting action. On the other hand, it has been found that the composition containing the lactic acid bacteria in addition to the composition II (composition IV) does not enhance the calcium absorption promoting effect of saponalin like the composition III but rather reduces it. However, unexpectedly, in addition to the composition II, the composition containing the green tea and the lactic acid bacteria (composition V) was found to be extremely excellent in the calcium absorption promoting action.

実施例5〜34(粉末飲料の製造)
下記処方例に記載の配合比に従って原料を調製したのち、常法に従って、本発明の効果を奏する粉末飲料を製造した。
Examples 5 to 34 (Production of Powdered Beverages)
After the raw materials were prepared according to the compounding ratio described in the following formulation example, a powdered beverage exhibiting the effects of the present invention was manufactured according to a conventional method.

本発明によれば、サポナリンの新たな有用性を提供することができる。また、優れたカルシウム吸収促進作用を有する組成物を提供することができる。 According to the present invention, it is possible to provide new utility of saponarin. In addition, a composition having an excellent calcium absorption promoting action can be provided.

Claims (2)

サポナリン及びカルシウムを含有する組成物。 A composition containing saponalin and calcium. さらに、不発酵茶を含有する請求項1に記載の組成物。 The composition according to claim 1, further comprising unfermented tea.
JP2017249145A 2017-12-26 2017-12-26 Composition Active JP6399419B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017249145A JP6399419B1 (en) 2017-12-26 2017-12-26 Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017249145A JP6399419B1 (en) 2017-12-26 2017-12-26 Composition

Publications (2)

Publication Number Publication Date
JP6399419B1 JP6399419B1 (en) 2018-10-03
JP2019110875A true JP2019110875A (en) 2019-07-11

Family

ID=63708629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017249145A Active JP6399419B1 (en) 2017-12-26 2017-12-26 Composition

Country Status (1)

Country Link
JP (1) JP6399419B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020250960A1 (en) 2019-06-14 2020-12-17 古河機械金属株式会社 Method for producing inorganic material and inorganic material production device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11221060A (en) * 1998-02-06 1999-08-17 Yoshio Yamamoto Drink containing fine powder of hordeum vulgare young leaf and/or medicago sativa l.
JP2003144093A (en) * 2001-11-09 2003-05-20 Toyo Shinyaku:Kk Health food
JP2005210972A (en) * 2004-01-29 2005-08-11 Hamaotome Co Ltd Powdered food and method for producing the same
JP2008184459A (en) * 2007-01-31 2008-08-14 Unitika Ltd Calcium absorption accelerating composition
JP2009084194A (en) * 2007-09-28 2009-04-23 Nippon Yakuhin Kaihatsu Kk 15-lipoxygenase inhibitor
JP2015127311A (en) * 2013-12-27 2015-07-09 株式会社東洋新薬 Cosmetics composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11221060A (en) * 1998-02-06 1999-08-17 Yoshio Yamamoto Drink containing fine powder of hordeum vulgare young leaf and/or medicago sativa l.
JP2003144093A (en) * 2001-11-09 2003-05-20 Toyo Shinyaku:Kk Health food
JP2005210972A (en) * 2004-01-29 2005-08-11 Hamaotome Co Ltd Powdered food and method for producing the same
JP2008184459A (en) * 2007-01-31 2008-08-14 Unitika Ltd Calcium absorption accelerating composition
JP2009084194A (en) * 2007-09-28 2009-04-23 Nippon Yakuhin Kaihatsu Kk 15-lipoxygenase inhibitor
JP2015127311A (en) * 2013-12-27 2015-07-09 株式会社東洋新薬 Cosmetics composition

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
<HTTP://WWW.AOJIRU-YAMAMOTO.CO.JP/OIDOCS/AONOKOUBO.HTML>, JPN6018015774, 2015, ISSN: 0003789041 *
<HTTP://WWW.TAISHO.CO.JP/COMPANY/RELEASE/2007/2007031901.HTML>, JPN6018015778, 19 March 2007 (2007-03-19), ISSN: 0003789043 *
<HTTP://WWW.YU-WA.COM/1351.HTML>, JPN6018015772, 26 May 2015 (2015-05-26), ISSN: 0003789040 *
<HTTPS://WWW.AMAZON.CO.JP/DP/B00IEVDSVU>, JPN6018015776, 13 February 2014 (2014-02-13), ISSN: 0003789042 *
<HTTPS://WWW.AMAZON.CO.JP/DP/B078DDZMQ1>, JPN6018015771, 8 December 2017 (2017-12-08), ISSN: 0003789039 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020250960A1 (en) 2019-06-14 2020-12-17 古河機械金属株式会社 Method for producing inorganic material and inorganic material production device
EP4360764A2 (en) 2019-06-14 2024-05-01 Furukawa Co., Ltd. Method of producing inorganic material and apparatus of producing inorganic material

Also Published As

Publication number Publication date
JP6399419B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
CN106174045A (en) A kind of probiotics fermention calcium-supplementing preparation and preparation method thereof
JP2013241354A (en) Phosphodiesterase 2 inhibitor
CN106962939A (en) Prepare the fermentation composition and preparation method of the plant enzyme with weight-reducing degreasing effect
JP2009249315A (en) Mineral absorption promoter, and iron deficiency anemia-ameliorating agent or food composition
JP6829461B2 (en) Green leaf powder and composition
CN102356836A (en) Perilla frutescens nutritional healthcare chewable tablet and preparation method thereof
JP6008161B2 (en) Sleep improver
JP2017127231A (en) Composition for eating and drinking
JP2022100407A (en) Oral composition containing equol and collagen peptide
JP6399419B1 (en) Composition
JP2019034896A (en) Oral composition
JP4688555B2 (en) Low-density lipoprotein lowering agent in blood containing Ashitaba and chitosan or its derivatives
JP2006014730A (en) Food product
JP6872699B2 (en) Composition for promoting calcium absorption
CN102860513A (en) Natural antioxidant oral liquid of Kushui rose
CN111148438A (en) Food composition for preparing a product for dysphagia subjects and use thereof in an automatic dispensing machine
JP2022044826A (en) Oral composition
JP2019041661A (en) Health food
KR102440573B1 (en) Composition for Prebiotics Containing Poly-Gamma-Glutamate
KR20170012766A (en) Method for Manufacturing Extract Powder of Cattle Bone
JP5986285B1 (en) Calcium absorption promoter
JP2019142976A (en) Adjuvant
JP2020054255A (en) Oral composition
JP7385256B2 (en) Oral composition
JP6515257B1 (en) Composition for eating and drinking

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180110

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180110

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180823

R150 Certificate of patent or registration of utility model

Ref document number: 6399419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250